The J. Baker Foundation

The J. Baker Foundation

The J. Baker Foundation was formed in August 2013 by brothers Julian and Felix Baker, the co-founders of Baker Bros. Advisors LP. The Baker brothers built their wealth through a highly focused, long-duration public and private biotech investment strategy that generated outsized returns from concentrated bets on companies like Seattle Genetics, Genomic Health, and Incyte. The foundation translates that concentrated financial capital into charitable capital for a narrow set of causes, primarily higher education, healthcare innovation, food security, and educational access. Unlike many major foundations that build large internal program staffs, the Bakers run the foundation with the operational footprint of a family office, making grants to a curated list of institutions rather than issuing broad requests for proposals. The foundation does not disclose its grantmaking by dollar amount, but Altss estimates total assets of roughly $66 million based on public filings. The foundation's grantmaking pattern closely mirrors the Bakers' intellectual interests—historic gifts have supported Harvard University, where Julian Baker serves on the Board of Overseers, and Cold Spring Harbor Laboratory, a leading biomedical research institution. The foundation also directs capital toward food-security nonprofits, reflecting a secondary philanthropic priority that extends beyond the life-sciences focus of Baker Bros. Advisors. The foundation does not make program-related investments, mission-related investments, or participate in any co-investment structures—uncharacteristic of many large foundations that blur the line between endowment management and grantmaking. The foundation operates with minimal public-facing infrastructure. It maintains no dedicated website, does not publish an annual report, and employs no known professional staff beyond the principals themselves. In May 2024, the foundation disclosed its 2023 IRS Form 990-PF, the primary public window into its activities, confirming a continued pattern of grants to a compact roster of educational and healthcare institutions, 2024). This opacity is deliberate and mirrors the culture of Baker Bros. Advisors, which has historically communicated with investors through brief quarterly letters and rarely grants media interviews. Structurally, the foundation is distinct from most biotech-wealth philanthropic vehicles in its refusal to accept unsolicited proposals. This is not a foundation that sees itself as a public grantmaking institution—it functions more like a private giving vehicle for two investors who apply the same research rigor and concentration to their charitable giving that they apply to their portfolio. There is no pledge to spend down by a certain date, no public-facing DEI overlay, and no advisory board of external experts. The foundation remains a direct expression of the Baker brothers' intellectual priorities, with no known succession plan for grantmaking governance beyond the founding generation.